About the Company
We do not have any company description for Unicycive Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $UNCY News
Unicycive Therapeutics, Inc. (UNCY)
LOS ALTOS, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the ...
Unicycive Therapeutics (UNCY) Price Target Increased by 21.14% to 5.41
The average one-year price target for Unicycive Therapeutics (NasdaqCM:UNCY) has been revised to 5.41 / share. This is an ...
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
March 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with ...
Unicycive Therapeutics Inc (UNCY) Stock Showcases -11.30% 20-Day Moving Average
The stock of Unicycive Therapeutics Inc (UNCY) has seen a -14.38% decrease in the past week, with a -12.59% drop in the past month, and a 27.55% flourish in the past quarter. The volatility ratio for ...
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
LOS ALTOS, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage ...
Unicycive Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
LOS ALTOS, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage ...
Unicycive Therapeutics, Inc.: Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
March 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the "Company" or "Unicycive"), a clinical-stage biotechnology company developing therapies for patients with kidney ...
Loading the latest forecasts...